GSA Capital Partners LLP Purchases 57,566 Shares of Kiniksa Pharmaceuticals International, plc $KNSA

GSA Capital Partners LLP increased its holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 281.9% during the third quarter, HoldingsChannel reports. The institutional investor owned 77,984 shares of the company’s stock after acquiring an additional 57,566 shares during the quarter. Kiniksa Pharmaceuticals International comprises 0.3% of GSA Capital Partners LLP’s investment portfolio, making the stock its 20th biggest position. GSA Capital Partners LLP’s holdings in Kiniksa Pharmaceuticals International were worth $3,028,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in KNSA. EverSource Wealth Advisors LLC raised its holdings in shares of Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after acquiring an additional 532 shares in the last quarter. USA Financial Formulas bought a new position in shares of Kiniksa Pharmaceuticals International in the third quarter worth approximately $32,000. Nordea Investment Management AB raised its stake in Kiniksa Pharmaceuticals International by 0.7% in the third quarter. Nordea Investment Management AB now owns 131,074 shares of the company’s stock valued at $5,016,000 after purchasing an additional 914 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Kiniksa Pharmaceuticals International by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company’s stock valued at $507,000 after purchasing an additional 1,002 shares during the last quarter. Finally, Osaic Holdings Inc. bought a new stake in Kiniksa Pharmaceuticals International during the second quarter valued at approximately $31,000. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals International Stock Performance

NASDAQ:KNSA opened at $45.37 on Tuesday. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $18.25 and a fifty-two week high of $46.65. The firm has a market cap of $3.44 billion, a PE ratio of 100.82 and a beta of 0.06. The business has a 50 day moving average price of $42.29 and a 200-day moving average price of $39.07.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other news, COO Eben Tessari sold 12,048 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $41.56, for a total value of $500,714.88. Following the sale, the chief operating officer directly owned 16,666 shares in the company, valued at approximately $692,638.96. This trade represents a 41.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Mark Ragosa sold 17,845 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $43.28, for a total value of $772,331.60. Following the transaction, the chief financial officer owned 12,086 shares of the company’s stock, valued at approximately $523,082.08. This represents a 59.62% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 123,823 shares of company stock valued at $5,244,967 in the last quarter. Company insiders own 53.48% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Wedbush lifted their price objective on shares of Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the stock an “outperform” rating in a report on Tuesday, January 13th. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Zacks Research downgraded Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. The Goldman Sachs Group upped their target price on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Finally, Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 2nd. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $52.33.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.